GNLX GENELUX Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1231457 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-95.3%
TTM net income YoY-5.6%
TTM EPS YoY18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-396,200.0%
Net margin-373,362.5%
FCF margin-270,112.5%
EBITDA margin-393,262.5%
Returns
ROE-130.6%
ROA-95.4%
ROIC (approx.)-180.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue4,762.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $0 |
| R&D expense | $6.91M | $6.51M | $5.78M | $5.65M | $4.74M | $4.76M | $4.70M | $6.52M |
| SG&A expense | $3.49M | $3.14M | $3.39M | $3.77M | $3.45M | $3.03M | $3.12M | $3.23M |
| Operating income | -$10.40M | -$9.64M | -$9.17M | -$9.41M | -$8.19M | -$7.79M | -$7.82M | -$9.75M |
| Net income | -$10.29M | -$9.47M | -$8.93M | -$9.25M | -$7.95M | -$7.46M | -$7.49M | -$8.98M |
| EBITDA | -$10.39M | -$9.63M | -$9.16M | -$9.35M | -$8.13M | -$7.73M | -$7.76M | -$9.69M |
| EPS (basic) | -0.23 | -0.21 | -0.20 | — | -0.21 | -0.20 | -0.21 | — |
| EPS (diluted) | -0.23 | -0.21 | -0.20 | — | -0.21 | -0.20 | -0.21 | — |
| Weighted avg. shares (diluted) | 45.31M | 44.96M | 44.15M | — | 37.89M | 37.95M | 34.93M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.45M | $9.18M | $9.27M | $5.33M | $4.69M | $6.55M | $16.21M | $8.56M |
| Short-term investments | $1.00M | $9.50M | $16.90M | — | $16.22M | $21.43M | $18.90M | $22.33M |
| Current assets | $10.93M | $19.14M | $26.75M | $15.13M | $21.55M | $29.23M | $35.95M | $31.55M |
| PP&E, net | $7.32M | $4.60M | $3.08M | $2.17M | $1.79M | $1.34M | $1.29M | $1.32M |
| Total assets | $20.61M | $26.20M | $32.37M | $19.03M | $24.99M | $32.25M | $38.98M | $34.72M |
| Current liabilities | $9.40M | $8.00M | $7.27M | $6.22M | $5.13M | $6.99M | $7.69M | $6.90M |
| Total liabilities | $11.43M | $10.09M | $9.45M | $7.48M | $6.40M | $8.35M | $9.14M | $8.44M |
| Shareholders' equity | $9.18M | $16.11M | $22.92M | $11.54M | $18.59M | $23.90M | $29.85M | $26.27M |
| Shares outstanding | 45.49M | 45.10M | 44.84M | 38.14M | 38.05M | 37.76M | 37.73M | 34.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.93M | -$6.44M | -$6.06M | -$6.20M | -$6.58M | -$7.06M | -$5.43M | -$4.30M |
| Capital expenditure | $2.72M | $1.53M | $921,000 | $436,000 | $517,000 | $115,000 | $30,000 | $96,000 |
| Free cash flow | -$8.65M | -$7.98M | -$6.98M | -$6.63M | -$7.09M | -$7.17M | -$5.46M | -$4.40M |
| Investing cash flow | $5.78M | $5.97M | -$8.54M | $6.56M | $4.72M | -$2.65M | $3.51M | $6.67M |
| Financing cash flow | $409,000 | $387,000 | $18.54M | $276,000 | $0 | $52,000 | $9.57M | $91,000 |
| Depreciation & amortization | $10,000 | $10,000 | $9,000 | $60,000 | $61,000 | $62,000 | $59,000 | $57,000 |
| Stock-based compensation | $2.94M | $2.27M | $1.39M | $1.53M | $2.63M | $1.48M | $1.42M | $1.43M |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.